SNY Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sanofi SA (SNY) is not a strong buy at the moment for a beginner investor with a long-term strategy. While there are some positive developments, the lack of strong proprietary trading signals, mixed analyst ratings, and uncertainties surrounding leadership and pipeline replacement suggest holding off on investment until more clarity emerges.
The MACD is positive and expanding, indicating bullish momentum. The RSI is in the neutral zone at 74.907, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance levels (R1: 46.548 and R2: 47.452), which could limit immediate upside potential.
Japan's Ministry of Health approval for Dupixent as the first targeted therapy for bullous pemphigoid. Hedge funds have significantly increased their buying activity by 231.75% over the last quarter.
Leadership transition with Paul Hudson leaving and Belen Garijo taking over, raising concerns about strategic direction and pipeline replacement. Limited pipeline catalysts and concerns over growth challenges post-Dupixent loss of exclusivity. Mixed analyst ratings with multiple downgrades and reduced price targets.
No financial data available for the latest quarter.
Analyst ratings are mixed. Bernstein initiated coverage with an Outperform rating and a EUR 110 price target, while Citi, BofA, UBS, and Barclays have downgraded the stock or lowered price targets due to concerns over pipeline replacement and strategic risks.
